Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALXO |
---|---|---|
09:32 ET | 4749 | 2.39 |
09:34 ET | 500 | 2.37 |
09:36 ET | 3039 | 2.35 |
09:38 ET | 2100 | 2.35 |
09:39 ET | 700 | 2.375 |
09:41 ET | 300 | 2.36 |
09:43 ET | 2600 | 2.35 |
09:45 ET | 6383 | 2.34 |
09:48 ET | 800 | 2.36 |
09:50 ET | 1943 | 2.37 |
09:52 ET | 6179 | 2.35 |
09:54 ET | 600 | 2.33 |
09:56 ET | 3085 | 2.325 |
09:57 ET | 1712 | 2.33 |
09:59 ET | 1500 | 2.34 |
10:01 ET | 1525 | 2.33 |
10:03 ET | 1328 | 2.34 |
10:06 ET | 1160 | 2.33 |
10:08 ET | 1510 | 2.335 |
10:10 ET | 1497 | 2.33 |
10:12 ET | 700 | 2.34 |
10:14 ET | 4735 | 2.375 |
10:15 ET | 600 | 2.365 |
10:17 ET | 1428 | 2.37 |
10:19 ET | 605 | 2.38 |
10:21 ET | 1000 | 2.385 |
10:24 ET | 16459 | 2.395 |
10:26 ET | 772 | 2.4 |
10:28 ET | 425 | 2.3902 |
10:30 ET | 1000 | 2.405 |
10:32 ET | 2382 | 2.405 |
10:33 ET | 100 | 2.405 |
10:35 ET | 500 | 2.4 |
10:37 ET | 3468 | 2.395 |
10:39 ET | 622 | 2.39 |
10:42 ET | 4815 | 2.37 |
10:44 ET | 100 | 2.38 |
10:48 ET | 2276 | 2.395 |
10:50 ET | 5001 | 2.42 |
10:51 ET | 1000 | 2.43 |
10:53 ET | 450 | 2.43 |
10:55 ET | 1359 | 2.43 |
10:57 ET | 1700 | 2.43 |
11:00 ET | 5673 | 2.405 |
11:02 ET | 5294 | 2.405 |
11:04 ET | 200 | 2.4 |
11:06 ET | 3009 | 2.405 |
11:08 ET | 1524 | 2.4 |
11:09 ET | 9700 | 2.4283 |
11:11 ET | 5464 | 2.4 |
11:15 ET | 300 | 2.39 |
11:18 ET | 710 | 2.395 |
11:20 ET | 500 | 2.395 |
11:22 ET | 2193 | 2.38 |
11:24 ET | 1313 | 2.38 |
11:26 ET | 900 | 2.39 |
11:27 ET | 400 | 2.385 |
11:29 ET | 700 | 2.38 |
11:31 ET | 1948 | 2.375 |
11:33 ET | 400 | 2.375 |
11:36 ET | 1522 | 2.385 |
11:38 ET | 300 | 2.385 |
11:40 ET | 855 | 2.375 |
11:44 ET | 2030 | 2.375 |
11:45 ET | 200 | 2.385 |
11:47 ET | 400 | 2.385 |
11:49 ET | 1684 | 2.375 |
11:51 ET | 4300 | 2.38 |
11:54 ET | 558 | 2.37 |
11:56 ET | 500 | 2.36 |
11:58 ET | 2547 | 2.375 |
12:00 ET | 408 | 2.37 |
12:02 ET | 300 | 2.37 |
12:03 ET | 885 | 2.375 |
12:05 ET | 300 | 2.37 |
12:07 ET | 3556 | 2.385 |
12:09 ET | 200 | 2.385 |
12:12 ET | 7595 | 2.385 |
12:14 ET | 300 | 2.395 |
12:16 ET | 1347 | 2.38 |
12:18 ET | 1167 | 2.375 |
12:20 ET | 3148 | 2.39 |
12:21 ET | 12068 | 2.385 |
12:23 ET | 100 | 2.39 |
12:25 ET | 1100 | 2.395 |
12:27 ET | 100 | 2.4 |
12:30 ET | 400 | 2.4 |
12:32 ET | 792 | 2.41 |
12:34 ET | 651 | 2.4 |
12:36 ET | 1385 | 2.4 |
12:38 ET | 1100 | 2.4 |
12:39 ET | 2161 | 2.415 |
12:41 ET | 3580 | 2.43 |
12:43 ET | 200 | 2.435 |
12:45 ET | 7034 | 2.445 |
12:48 ET | 9698 | 2.47 |
12:50 ET | 500 | 2.465 |
12:52 ET | 18601 | 2.47 |
12:54 ET | 1400 | 2.48 |
12:56 ET | 3699 | 2.495 |
12:59 ET | 5019 | 2.505 |
01:01 ET | 3276 | 2.495 |
01:03 ET | 820 | 2.49 |
01:06 ET | 2176 | 2.49 |
01:08 ET | 1575 | 2.48 |
01:10 ET | 600 | 2.4891 |
01:12 ET | 20034 | 2.49 |
01:14 ET | 500 | 2.48 |
01:15 ET | 7701 | 2.4702 |
01:17 ET | 600 | 2.475 |
01:19 ET | 500 | 2.475 |
01:21 ET | 996 | 2.475 |
01:24 ET | 300 | 2.47 |
01:26 ET | 4713 | 2.465 |
01:28 ET | 1157 | 2.4701 |
01:30 ET | 1800 | 2.485 |
01:32 ET | 1806 | 2.4714 |
01:33 ET | 100 | 2.475 |
01:35 ET | 12486 | 2.46 |
01:37 ET | 700 | 2.45 |
01:39 ET | 400 | 2.45 |
01:42 ET | 3365 | 2.43 |
01:44 ET | 200 | 2.43 |
01:46 ET | 1113 | 2.43 |
01:48 ET | 412 | 2.425 |
01:50 ET | 9727 | 2.4102 |
01:51 ET | 3300 | 2.426 |
01:53 ET | 500 | 2.425 |
01:55 ET | 334 | 2.425 |
01:57 ET | 1632 | 2.425 |
02:00 ET | 5617 | 2.425 |
02:02 ET | 400 | 2.42 |
02:04 ET | 1055 | 2.43 |
02:06 ET | 800 | 2.42 |
02:08 ET | 1100 | 2.425 |
02:09 ET | 1100 | 2.425 |
02:11 ET | 9489 | 2.42 |
02:13 ET | 1828 | 2.415 |
02:15 ET | 600 | 2.43 |
02:18 ET | 2700 | 2.44 |
02:20 ET | 500 | 2.44 |
02:22 ET | 800 | 2.44 |
02:24 ET | 2000 | 2.435 |
02:26 ET | 968 | 2.44 |
02:27 ET | 1458 | 2.43 |
02:29 ET | 1500 | 2.435 |
02:31 ET | 1300 | 2.44 |
02:33 ET | 5114 | 2.4491 |
02:36 ET | 10223 | 2.466 |
02:38 ET | 996 | 2.475 |
02:40 ET | 200 | 2.475 |
02:42 ET | 838 | 2.48 |
02:44 ET | 1541 | 2.48 |
02:45 ET | 4426 | 2.47 |
02:47 ET | 16085 | 2.476 |
02:49 ET | 859 | 2.49 |
02:51 ET | 500 | 2.49 |
02:54 ET | 1000 | 2.485 |
02:56 ET | 1157 | 2.49 |
02:58 ET | 4411 | 2.49 |
03:00 ET | 500 | 2.495 |
03:02 ET | 1700 | 2.495 |
03:03 ET | 10657 | 2.49 |
03:05 ET | 700 | 2.49 |
03:07 ET | 635 | 2.4937 |
03:09 ET | 200 | 2.495 |
03:12 ET | 3300 | 2.5 |
03:14 ET | 1200 | 2.51 |
03:16 ET | 753 | 2.51 |
03:18 ET | 1300 | 2.51 |
03:20 ET | 1148 | 2.505 |
03:21 ET | 13866 | 2.525 |
03:23 ET | 1800 | 2.525 |
03:25 ET | 24513 | 2.495 |
03:27 ET | 8169 | 2.52 |
03:30 ET | 27614 | 2.51 |
03:32 ET | 2500 | 2.495 |
03:34 ET | 1200 | 2.5 |
03:36 ET | 9006 | 2.485 |
03:38 ET | 9790 | 2.49 |
03:39 ET | 16388 | 2.51 |
03:41 ET | 2000 | 2.51 |
03:43 ET | 16858 | 2.545 |
03:45 ET | 9736 | 2.54 |
03:48 ET | 3500 | 2.54 |
03:50 ET | 16804 | 2.5489 |
03:52 ET | 21883 | 2.58 |
03:54 ET | 15008 | 2.565 |
03:56 ET | 19597 | 2.545 |
03:57 ET | 18539 | 2.53 |
03:59 ET | 139614 | 2.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ALX Oncology Holdings Inc | 125.9M | -0.7x | --- |
Tiziana Life Sciences Ltd | 125.8M | -7.1x | --- |
X4 Pharmaceuticals Inc | 126.4M | 8.5x | --- |
Annovis Bio Inc | 126.5M | -2.2x | --- |
Athira Pharma Inc | 127.6M | -1.1x | --- |
PDS Biotechnology Corp | 123.3M | -2.6x | --- |
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $125.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-3.64 |
Book Value | $3.80 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.